Needham Maintains Buy on Jazz Pharmaceuticals, Raises Price Target to $292

Benzinga Newsdesk www.benzinga.com Positive 81.4%

Neg 0% Neu 0% Pos 81.4%

Needham analyst Ami Fadia maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Buy and raises the price target from $282 to $292.